Gergely Gulyás shared the number of illnesses and deaths after Hungary's second inoculations, concluding that the numbers support vaccination effectiveness.
US Medical Journal: Sinopharm Effective Against Coronavirus
The Journal of the American Medical Association (JAMA) shared the entire documentation of the Sinopharm vaccine, developed by China National Biotec Group Company (CNBG). The study, overwhelmingly made up of younger, healthy male volunteers, concluded that the vaccine is 72.8 and 78.1 percent effective against the coronavirus.
The long-awaited phase three clinical trials of the Sinopharm vaccine have finally been shared, showing that it is effective. The large scale study involved 40,832 volunteers from the United Arab Emirates, Bahrain, Egypt, and Jordan.
Very Few Elders in Sinopharm Vaccine Clinical Trials
Participants were either given two doses within three weeks or a placebo. Two weeks before their second inoculation, significantly more non-vaccinated people had caught the virus than those who were vaccinated at least once.
WHO Gives Sinopharm Vaccine International Emergency Licensing
The World Health Organization (WHO) has given the Chinese Sinopharm vaccine international emergency authorization, announced from its Geneva headquarters. The Hungarian government has reacted to the declaration, stating that it “disproves the left-wing opposition’s” arguments against the vaccine.”
With support from an internationally recognized body of the world’s leading scientist, the Chinese Sinopharm vaccine’s credibility has sky-rocketed, and it can now be rolled out globally.
Professors, virologists, and virus researchers around Hungary continue to emphasize it; all vaccines authorized in Hungary are effective. Chief infectologist of the South Pest Hospital Centre, virologist János Szlávik sat down with Hungary Today at the beginning of the year to discuss vaccination and the race against the coronavirus. Chief Infectologist: Herd Immunity Needed Szlávik […]Continue reading
Katalin Karikó, the Hungarian biochemist who was fundamental in the creation of Pfizer-BioNTech’s vaccine, is currently in Hungary until May 27. While her schedule and work responsibilities have kept her very busy, since she has arrived she has spoken at the Hungarian Academy of Science (MTA), given interviews to Hungarian media, and met with the rector of Semmelweis University, Béla Merkely.
At her speech for the 194th conference of the Hungarian Academy of Science (MTA), Katalin Karikó spoke about her career path, which started at the University of Szeged, and gave details on the scientific know-how of messenger ribonucleic acid (mRNA) technology. It was Karikó’s decades of hard work which led to this technology becoming the foundation for Pfizer-BioNTech’s coronavirus vaccine.
FM Szijjártó: Hungarian Opposition Fails on Chinese Covid Vaccine Sinopharm
The Hungarian opposition has ultimately proved wrong in its position on rejecting China’s Covid-19 vaccine, the foreign minister said on Friday afternoon, after the World Health Organisation (WHO) approved Sinopharm for emergency use.
“The world’s best experts have asserted that Sinopharm is an effective and safe vaccine,” Péter Szijjártó told public media.
The minister said that WHO is the world’s top decision-making body on health issues with the best and most experienced doctors, epidemiologists and virologists working in its ranks. These experts have thoroughly examined every Covid-19 vaccine including Sinopharm, of which Hungary has procured 5 million doses and used it to inoculate several hundreds of thousands of its citizens, Szijjártó said.